Perspective Therapeutics (CATX) Net Margin

Graphic logo of Perspective Therapeutics Inc (CATX)

Perspective Therapeutics (CATX) shows volatility in its net profit margin history, despite the global immunity of radiopharmaceuticals to trade sanctions. This decline is driven by the high cost of hiring rare nuclear medicine specialists and a reliance on air logistics due to the short half-life of isotopes. The current -55866.80 determines the magnitude of the metric, reflecting management's efficiency in controlling cost of sales amid external shocks.

Perspective Therapeutics, Inc. (CATX) Return on Sales by Net Profit: for the period 06/21/2023 - 11/19/2026

Analytical breakdowns for perspectivetherapeutics.com (CATX)

Comprehensive company analysis:Perspective Therapeutics
Manufactured product of Perspective Therapeutics

The seamless operation of the Perspective Therapeutics (CATX) express air delivery system for radiopharmaceuticals minimizes operational losses from isotope decay, directly impacting bottom-line profitability. An analysis of the business's net margin efficiency demonstrates the share of net income in revenue, allowing for an assessment of the real return on capital and the company's scaling potential, despite persistent risks of volatility in industry demand.